France Cancer Vaccines Market Insight
Published: 02 June 2026 | Report Format: Electronic (PDF)
The France Cancer Vaccines market size is growing at a 14.8% CAGR, driven by the rising immunotherapy adoption and expansion of personalized oncology treatment approaches.
France Cancer Vaccines Market Insights Forecasts to 2035
- The France Cancer Vaccines Market Size Was Estimated at USD 365.08 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 14.8% from 2025 to 2035
- The France Cancer Vaccines Market Size is Expected to Reach USD 1450.9 Million by 2035
Notable Insights for France Cancer Vaccines Market
- The therapeutic cancer vaccines segment dominates the France cancer vaccines market and generated approximately USD 245 million in revenue during 2025. Scientists now concentrate on developing cancer vaccines which activate the immune system to fight existing tumors which makes this segment the market leader.
- The market for mRNA-based vaccines and personalized cancer treatments will experience fast expansion between now and the forecast period because of an expected 18% annual growth rate. The expansion of this field receives its momentum from three main factors which include precision medicine breakthroughs and genomic sequencing progress and personalized immunotherapy treatment development.
- The European cancer vaccine market receives about 10% of its revenue from France because the country maintains a strong foundation for oncology research and biopharmaceutical development.
- The French cancer vaccine market derives about 68% of its revenue from therapeutic vaccines because scientists currently concentrate their efforts on developing treatment-based immunotherapies.
Download the eBook (ToC)
Why Buy This Report
- Gain comprehensive insights into the France cancer vaccines market, including market size, growth trends, competitive landscape, and future forecast analysis shaping the oncology immunotherapy industry.
- Analyze rising demand for cancer vaccine technologies across hospitals, cancer centers, research institutes, biotechnology companies, and precision medicine ecosystems in France.
- Identify high-growth investment opportunities through detailed evaluation of mRNA vaccine technologies, personalized oncology platforms, neoantigen-based therapies, and AI-driven immunotherapy development solutions influencing the France cancer vaccines market.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the France Cancer Vaccines market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in France Cancer Vaccines Market
- BioNTech SE
- Moderna, Inc.
- Merck & Co., Inc.
- GSK plc
- Sanofi S.A.
- Roche Holding AG
- AstraZeneca PLC
- Pfizer Inc.
- Transgene S.A.
- CureVac N.V.
- Bristol Myers Squibb Company
- Genentech, Inc.
- Others
Recent Developments:
- In March 2025, oncology biotechnology companies expanded clinical development programs for personalized mRNA cancer vaccines targeting melanoma, lung cancer, and colorectal cancer indications.
- In February 2025, cancer research institutions increased investment in neoantigen identification technologies designed to improve therapeutic vaccine effectiveness.
Market Segmentation:
France Cancer Vaccines Market, By VaccineType
- Preventive Cancer Vaccines
- Therapeutic Cancer Vaccines
France Cancer Vaccines Market, By Technology
- mRNA Cancer Vaccines
- Neoantigen-Based Vaccines
- Dendritic Cell Vaccines
- Peptide-Based Vaccines
- Viral Vector-Based Vaccines
- Others
France Cancer Vaccines Market, By Cancer Type
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Melanoma
- Cervical Cancer
- Others
Expert Views:
Industry experts believe the France cancer vaccines market will continue growing rapidly because precision oncology, immunotherapy innovation, and personalized medicine increasingly depend on targeted immune-based treatments. The strongest opportunity lies in mRNA cancer vaccines, neoantigen-based immunotherapies, AI-driven biomarker discovery platforms, and personalized oncology solutions that improve treatment efficacy, patient outcomes, and long-term cancer management.
Author: Komal and Pranali By Spherical Insights and Consulting